“…Many of the patient-/caregiver-reported and clinician-reported barriers to HPV vaccination for the general population [ 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 ] overlap with those reported for PYAC survivors [ 41 , 42 , 68 , 69 , 70 , 71 ], whereas some barriers are unique to the PYAC survivor population ( Table 1 ). For instance, PYAC survivors and their caregivers reported concerns about the safety, side effects, and applicability of the HPV vaccine in relation to their cancer history and survivorship [ 41 , 68 , 72 ]. Cherven et al discovered that cancer survivors exhibited a higher tendency to decline participation in an open-label trial investigating the immunogenicity and safety of the HPV vaccine due to concerns regarding its safety [ 72 ].…”